Pfizer (NYSE:PFE) Trading Down 1.5% – Here’s What Happened

Shares of Pfizer Inc. (NYSE:PFE) dropped 1.5% on Monday . The company traded as low as $25.60 and last traded at $25.6550. Approximately 39,882,553 shares were traded during trading, a decline of 3% from the average daily volume of 41,152,750 shares. The stock had previously closed at $26.04.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer is advancing its obesity pipeline with a new mid-stage SOLIS-1 trial, reinforcing hopes that it can compete in the large GLP-1/weight-loss market. Article Title
• Positive Sentiment: Pfizer also reported encouraging obesity data, with its drug showing 16% weight loss in a phase 2b study, supporting the idea that the company could build a meaningful new growth franchise. Article Title
• Positive Sentiment: RBC Capital Markets upgraded Pfizer, saying the recent share weakness has made the risk-reward profile more attractive ahead of two key pipeline catalysts. Article Title
• Positive Sentiment: Pfizer’s HYMPAVZI won expanded FDA approval for pediatric hemophilia A and B patients, broadening the drug’s commercial opportunity in rare disease. Article Title
• Neutral Sentiment: Pfizer announced an update on its pneumococcal vaccine trial, but the available details only indicate ongoing study progress rather than a clear positive or negative surprise. Article Title
• Negative Sentiment: Reuters reported that Pfizer’s CEO warned Germany that planned drug-pricing policies could put future investment there at risk, highlighting ongoing regulatory pressure on pricing and margins. Article Title

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent analyst reports. Bank of America dropped their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a report on Thursday, February 12th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Pfizer in a report on Monday, June 1st. HSBC upped their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Finally, Barclays initiated coverage on Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.82.

Pfizer Price Performance

The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The stock has a market cap of $145.93 billion, a price-to-earnings ratio of 19.55 and a beta of 0.34. The stock has a fifty day moving average of $26.56 and a two-hundred day moving average of $26.31.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s dividend payout ratio is 131.30%.

Institutional Trading of Pfizer

Several large investors have recently bought and sold shares of the company. Pine Valley Investments Ltd Liability Co grew its holdings in Pfizer by 2.3% in the first quarter. Pine Valley Investments Ltd Liability Co now owns 145,531 shares of the biopharmaceutical company’s stock valued at $4,087,000 after purchasing an additional 3,281 shares during the last quarter. Farmers National Bank grew its holdings in Pfizer by 1.9% in the first quarter. Farmers National Bank now owns 83,303 shares of the biopharmaceutical company’s stock valued at $2,339,000 after purchasing an additional 1,546 shares during the last quarter. Chelsea Counsel Co. acquired a new stake in Pfizer in the first quarter valued at $562,000. Wealthquest Corp boosted its stake in shares of Pfizer by 12.3% during the first quarter. Wealthquest Corp now owns 20,683 shares of the biopharmaceutical company’s stock valued at $581,000 after acquiring an additional 2,263 shares during the last quarter. Finally, Parallel Advisors LLC boosted its stake in shares of Pfizer by 49.3% during the first quarter. Parallel Advisors LLC now owns 129,199 shares of the biopharmaceutical company’s stock valued at $3,628,000 after acquiring an additional 42,667 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.